Refractory Ovarian Carcinoma

Explore clinical trials studying Refractory Ovarian Carcinoma. Study availability and eligibility vary by location and protocol.

9 public trials 4 recruiting studies

Refine in advanced search Browse all conditions

Refractory Ovarian Carcinoma trial results

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

NCT04055649

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +24 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

Karmanos Cancer Institute at McLaren Flint Flint, Michigan, United States

View Trial Details

Recruiting

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

NCT06483048

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +30 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

View Trial Details

Recruiting

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

NCT06315491

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +14 more
Locations: Honor Health Scottsdale, Arizona, United States

Arizona Oncology Associates Tucson, Arizona, United States

Usc Norris Comprehensive Cancer Center Los Angeles, California, United States

Yale University School of Medicine New Haven, Connecticut, United States

View all 17 locations

View Trial Details

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

NCT05733000

Conditions: Adenocarcinoma, Adenocarcinoma of Lung, Adnexal Diseases, +67 more
Locations: Northwestern University Chicago, Illinois, United States

View Trial Details

Completed

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03026062

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

NCT03784677

Conditions: Adnexal Diseases, Advanced Malignant Solid Neoplasm, Digestive System Diseases, +44 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT03756818

Conditions: Adnexal Diseases, Advanced Malignant Solid Neoplasm, Endocrine Gland Neoplasms, +16 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04753216

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations: Northwestern University Chicago, Illinois, United States

View Trial Details

Active, Not Recruiting

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03907527

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +48 more
Locations: National Institutes of Health (NIH) Bethesda, Maryland, United States

Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Refractory Ovarian Carcinoma

Refractory Ovarian Carcinoma trial results

Related conditions